Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma

NCT02624440 is registered in ClinicalTrials.gov with Henrik Gregersen as lead sponsor.

NCT NCT02624440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02624440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Henrik Gregersen
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2013
Completion date
July 31, 2017
Enrollment
300 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

infection, multiple myeloma